GANX
Gain Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.80
−1.10%Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- -$0.13
- Revenue estimate
- $33.3K
Latest reported
- Last report date
- Aug 11, 2026
- EPS actual
- -$0.11
- EPS estimate
- -$0.14
- Revenue actual
- —
- Revenue estimate
- $33.3K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 3
- Avg surprise (4Q)
- +10.4%
- Revenue beats (12Q)
- 1
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $6.50
- PT range
- $5.00 – $8.00
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026